Telix Pharmaceuticals (NASDAQ:TLX) Price Target Cut to $22.00 by Analysts at Citigroup

Telix Pharmaceuticals (NASDAQ:TLX) had its price target lowered by equities research analysts at Citigroup from $22.50 to $22.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 87.15% from the company’s current price.

TLX has been the topic of a number of other research reports. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Price Performance

TLX traded down $0.40 during trading on Tuesday, reaching $11.76. 75,578 shares of the stock were exchanged, compared to its average volume of 215,724. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $16.98. The business’s 50 day moving average price is $10.27 and its two-hundred day moving average price is $8.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Insiders Place Their Bets

In related news, CEO Christian Behrenbruch bought 33,435 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were acquired at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the acquisition, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. The trade was a 0.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in TLX. Rhumbline Advisers grew its stake in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter valued at $89,000. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth about $120,000. Finally, IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.